Claims
- 1. A method for treating a cancer subject comprising administering to the subject a combination of ATP-depleting agents at concentrations which deplete the ATP level to, or close to, at least 15% of normal in cancer cells.
- 2. The method of claim 1, further comprising a pyrimidine-depleting agent.
- 3. The method of claim 1, further comprising an anticancer agent.
- 4. The method of claim 1, wherein the cancer is clinically sensitive to the employed anti-cancer agent.
- 5. A method for induction of cancer cell death comprising contacting said cancer cell with a combination of ATP-depleting agents at concentrations which deplete the ATP level to at least 15% of normal in cancer cells.
- 6. The method of claim 5, further comprising a pyrimidine-depleting agent.
- 7. The method of claim 5, further comprising an anticancer agent.
- 8. The method of claim 5, wherein the cancer is clinically sensitive to the employed anticancer agent.
- 9. A method for treating a cancer subject, and for the induction of cancer cell death, comprising administering to the subject a combination of ATP-depleting agents, plus a pyrimidine antagonist, and plus an anticancer agent to which the treated cancer is sensitive, at concentrations which together collectively deplete the ATP levels to at least 15% of normal in cancer cells.
- 10. The method of claim 1-9 wherein the ATP-depleting agents comprise 6-methylmercaptopurine riboside (MMPR), 6-Aminonicotinomide (6-AN) and alanosine (AL).
- 11. The method of claim 10, further comprising N-(phosphonacetyl)-L-aspartic acid (PALA).
- 12. The method of claim 10 wherein the ATP-depleting agents comprise 6-methylmercaptopurine riboside (MMPR) and alanosine (AL).
- 13. The method of claim 12 further comprising N-(phosphonacetyl)-L-aspartic acid (PALA).
- 14. The method of claim 13 further comprising dehydroepiandrosterone (DHEA).
- 15. The method of claim 13 further comprising oxythiamine (OT).
- 16. The method of claim 13 further comprising dehydroepiandrosterone (DHEA) and oxythiamine (OT).
- 17. The method of claim 16 further comprising 6-Aminonicotinomide (6-AN).
- 18. A method of claim 1-17 further comprising an anti-myelosuppression agent.
- 19. The method of claim 18, wherein the anti-myelosuppression agent is G-CSF.
- 20. A composition comprising a combination of ATP-depleting agents at concentrations which deplete the ATP level to at least 15% of normal in cancer cells, a pyrimidine antagonist, and an anticancer agent to which the treated cancer is sensitive.
- 21. A composition comprising an effective amount of a combination of ATP-depleting agents at concentrations which deplete the ATP level to at least 15% of normal in cancer cells, a pyrimidine antagonist, and an anticancer agent to which the treated cancer is sensitive.
- 22. The composition of claim 20, further comprising a pyrimidine-depleting agent.
- 23. The composition of claim 20, further comprising an anticancer agent to which the cancer is sensitive.
- 24. The composition of claim 20-23, wherein the ATP-depleting agents comprise 6-methylmercaptopurine riboside (MMPR), 6-Aminonicotinomide (6-AN) and alanosine (AL).
- 25. The composition of claim 24, further comprising N-(phosphonacetyl)-L-aspartic acid (PALA).
- 26. A composition of claim 20-23 wherein the ATP-depleting agents comprise 6-methylmercaptopurine riboside (MMPR) and alanosine (AL).
- 27. A composition of claim 26 further comprising N-(phosphonacetyl)-L-aspartic acid (PALA).
- 28. A composition of claim 26 further comprising dehydroepiandrosterone (DHEA).
- 29. A composition of claim 26 further comprising oxythiamine (OT).
- 30. A composition of claim 26 further comprising dehydroepiandrosterone (DHEA) and oxythiamine (OT).
- 31. A composition of claim 26 further comprising 6-Aminonicotinomide (6-AN).
- 32. A composition of claim 20-31 further comprising an anti-myelosuppression agent.
- 33. A composition of claim 32 wherein the anti-myelosuppression agent is G-CSF.
- 34. A pharmaceutical composition comprising the composition of claim 20-33 and a pharmaceutically acceptable carrier.
- 35. A method for treating a subject bearing cancer cells comprising administering to the subject an anticancer agent at a concentration capable of inducing necrosis in cancer cells.
- 36. The method of claim 35, wherein the agent is an ATP-depleting regimen.
- 37. The method of claim 35 further comprising a pyrimidine-depleting agent.
- 38. The method of claim 35 further comprising an anticancer agent.
- 39. The method of claim 35, wherein the cancer is clinically sensitive to the employed anti-cancer agent.
- 40. A method for induction of cancer cell death comprising contacting said cancer cell with an agent capable of inducing necrosis in cancer cells.
- 41. The method of claim 40, wherein the agent is an ATP-depleting agent.
- 42. The method of claim 40 further comprising a pyrimidine-depleting regimen.
- 43. The method of claim 40 further comprising an anticancer agent.
Parent Case Info
[0001] This application claims priority of U.S. Ser. No. 60/250,993, filed Dec. 4, 2000, and International PCT/US01/46886, filed Dec. 4, 2001, the contents of which are hereby incorporated into this application by reference.
Government Interests
[0002] The invention disclosed herein was made with government support under National Cancer Institute RAID Grant Application #153. Accordingly, the U.S. Government has certain rights in this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60250993 |
Dec 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCT/US01/46886 |
Dec 2001 |
US |
Child |
10172346 |
Jun 2002 |
US |